| Identification | Back Directory | [Name]
AJI-214 | [CAS]
1395886-20-0 | [Synonyms]
AJI-214
Benzamide, 4-[[4-[(2-chlorophenyl)amino]-5-fluoro-2-pyrimidinyl]amino]- | [Molecular Formula]
C17H13ClFN5O | [MOL File]
1395886-20-0.mol | [Molecular Weight]
357.77 |
| Chemical Properties | Back Directory | [Melting point ]
250-252 °C | [Boiling point ]
562.434±60.00 °C(Press: 760.00 Torr)(predicted) | [density ]
1.473±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | [pka]
16.133±0.50(predicted) |
| Hazard Information | Back Directory | [Uses]
AJI-214 is a dual-target inhibitor of Aurora kinase A and JAK2. AJI-214 directly blocks Aurora kinase A to inhibit T cell mitotic progression and cell polarity, and inhibits JAK2 activation to inhibit STAT3 phosphorylation, thereby reducing the differentiation of TH1 and TH17 cells. AJI-214 can be used in studies on regulating immune responses and preventing graft-versus-host disease (GVHD)[1]. | [References]
[1] Betts, et al. "Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function." Science translational medicine 9.372 (2017): eaai8269. DOI:10.1126/scitranslmed.aai8269 |
|
|